T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... heart failure in 2021 and secured an expanded label in a hard-to-treat population the next year.

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: ...

The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that ...

Studies show Zepbound can improve the condition by reducing ... Mounjaro to treat Type 2 diabetes and became popular as an off-label weight-loss treatment. Tirzepatide works by stimulating two ...

Calorie labels in supermarkets and restaurants have little impact on consumer choices, researchers found, fueling doubts ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are generating billions ... diabetes and rocketed to new heights as off-label prescriptions for obesity made it a cultural ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...